19 May 2022AmericasMuireann Bolger

USPTO urges Vidal review of Arthrex petition

The US Patent and Trademark Office (USPTO) has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Vidal steps up scrutiny of Fintiv rule-based decisions

6 September 2022 Mylan and Edwards Lifesciences argue that the controversial rule safeguards poor-quality patents | US v Arthrex conferred increased authority to Vidal over PTAB decisions.

Americas

Senators urge USPTO to curb ‘patent thicket’ abuse

9 June 2022 A bipartisan group of six US senators have asked the US Patent and Trademark Office to address ‘patent thickets’, a tactic that pharmaceutical companies allegedly use to stifle competition.

Medtech

Arthrex petitions Fed Circ again over ‘inferior officers’

13 January 2022 Arthrex says that it did not get the “remedy” ordered by the US Supreme Court in its landmark case against Smith & Nephew.